訪問生物技術

2023年2月21日

2023年2月21日Hemab療法,臨床分期生物科技公司發展中第一個預防性治療嚴重的出血和血栓性疾病,今天宣布關閉係列B超額認購1.35億美元融資。訪問生物技術引領一輪,新投資者的參與深度追蹤資本,Avoro Ventures Invus,岩石泉資本和Maj投資股權,以及所有當前投資者Novo控股,RA Capital Management, HealthCap。“Hemab從根本上重塑缺醫少藥出血和血栓性疾病的治療模式。這個融資將使我們進步臨床項目第一預防性治療Glanzmann血小板機能不全和血管性血友病,實現功能治療病人的需要,“本尼索倫森說,醫學博士,首席執行官& Hemab總統。“我們感激這健壯的辛迪加的投資者支持我們的方法利用先進技術進行驗證和深入的生物學凝血克服幾十年的科學停滯。“融資將支持Hemab科學和企業增長計劃到2025年,包括完成的1/2期臨床研究的領先候選人hmb - 001 Glanzmann血小板機能不全,起始的關鍵研究,開始和完成1/2期臨床評估HMB-VWF血管性血友病,進化和未來管道按照公司戰略guidance-targeting Hemab 1-2-5™開發5臨床資產2025。“強大的投資者信心,這種情況下,一個更大的圓和超過2億美元的需求證明Hemab的專業團隊,他們驗證科學方法,和機會帶來期待已久的創新與嚴重的出血和血栓性疾病患者,”約翰·Maraganore說博士Hemab董事會主席。”成立投資者和公司的最大股東,我們興奮地支持Hemab計劃的下一階段構建最終的凝血公司,與一個北歐基金會和全球足跡,“說Jørgen Søberg彼得森,醫學博士,博士學位,MBA,新生的合夥人持有。Hemab還宣布丹貝克,醫學博士,董事總經理訪問,和Uya Chuluunbaatar,博士Avoro Ventures合夥人也將加入董事會。克裏斯汀博羅夫斯基博士、副總裁訪問將加入董事會觀察員。 “We are thrilled to partner with Hemab’s exceptional leadership to advance a pipeline of transformative new medicines for areas of high unmet need in hemostatic disorders,” said Dr. Becker. About Hemab Therapeutics Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. Learn more at hemab.com . About HMB-001 HMB-001 is bispecific antibody that binds and stabilizes endogenous factor VIIa (FVIIa) with one antibody arm and TLT-1 on activated platelets with the other arm. This allows for accumulation of FVIIa in the body, recruitment of FVIIa directly to the surface of the activated platelets where it is known to facilitate clotting, and avoidance of clotting activity in the absence of tissue damage. HMB-001 was designed to be a first-in-class prophylactic treatment for Glanzmann Thrombasthenia with potential for other debilitating rare bleeding disorders. It entered Phase 1/2 clinical evaluation in late 2022, with initial data expected 2H 2023.